Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
Jen Smith
Jen Smith is the medical editor of Cancer Therapy Advisor. She was previously the editor of Hematology Times and the oncology editor for MDedge Hematology/Oncology. She has a BS in journalism.
